Schizophrene und schizophreniforme Störungen

Ackenheil M, Bondy B (1996) The value of biological markers in genetic research. In: Mendlewicz J, Papadimitriou GN (eds) Clinical psychiatry. Mental disorders. Bailliere Tindall, London, p 135–148Google Scholar

Amato T, Rochet T, Dalery J, Chauchat JH, Martin JP, Marie-Cardine M (1994) Saisonality of birth and ventricular enlargement in chronic schizophrenia. Psychiatry Res 55: 65–73PubMedGoogle Scholar

Bebbington P, Kuipers L (1994) The predictive utility of expressed emotion in schizophrenia: an aggregate analysis. Psychol Med 24: 707–718PubMedGoogle Scholar

Bogerts B, Lieberman JA, Ashtari M et al. (1993) Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry 33: 236–246CrossRefPubMedGoogle Scholar

Davis JM, Kane JM, Marder SR et al. (1993) Dose response of prophylactic antipsychotics. J Clin Psychiatry 54[Suppl]: 24–30PubMedGoogle Scholar

Kane JM, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19: 287–302PubMedGoogle Scholar

Mari JDJ, Streiner DL (1994) An overview of family interventions and relapse on schizophrenia: Meta-analysis of research findings. Psychol Med 24:565–578PubMedGoogle Scholar

McCarley RW, Hsiao JK, Freedman R, Pfefferbaum A, Donchin E (1996) Neuroimaging and the cognitive neuroscience of schizophrenia. Schizophr Bull 22: 703–725PubMedGoogle Scholar

Meltzer HY (1992) Treatment of the neuroleptic, non-responsive schizophrenic patient. Schizophr Bull 18: 515–542PubMedGoogle Scholar

Möller HJ (1993) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3: 1–11PubMedGoogle Scholar

Möller HJ (1996) Treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 246: 229–234..CrossRefPubMedGoogle Scholar

Möller HJ (2000) Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 1: 75–91PubMedGoogle Scholar

Möller HJ (2000) State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 1: 204–214PubMedGoogle Scholar

Norman RMG, Malla AK (1993) Stressful life events and schizophrenia. I. A review of research. Br J Psychiatry 62: 161–166Google Scholar

Riedel M, Müller N, Möller HJ (1999) Die Psychopharmakotherapie der Schizophrenie. Psychotherapie 4: 48–55Google Scholar

Riedel M, Schaub A, Möller HJ, Müller N (1999) Pathogenetische Modellvorstellungen zur Schizophrenie. Psychotherapie 4: 108–114Google Scholar

Yank GR, Bentley KJ, Hargrove DS (1993) The vulnerability-stress-model of schizophrenia: Advances in psychological treatment. Am J Orthopsychiatry 63: 55–69PubMedGoogle Scholar